You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetoprofen
Accession NumberDB01009  (APRD01059, DB05823, DB05335)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionKetoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Structure
Thumb
Synonyms
2-(3-Benzoylphenyl)propionic acid
3-Benzoyl-alpha-methylbenzeneacetic acid
3-Benzoyl-α-methylbenzeneacetic acid
3-Benzoylhydratropic acid
Ketoprofen
L'Acide (benzoyl-3-phenyl)-2-propionique
m-Benzoylhydratropic acid
Orudis (tn)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketoprofencapsule50 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen SRtablet (extended-release)200 mgoralAa Pharma Inc1995-12-31Not applicableCanada
Ketoprofen Suppositoriessuppository50 mgrectalPharmel IncNot applicableNot applicableCanada
Ketoprofen Suppositoriessuppository100 mgrectalPharmel Inc1998-06-04Not applicableCanada
Ketoprofen-Etablet (enteric-coated)100 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen-Etablet (enteric-coated)50 mgoralAa Pharma Inc1989-12-31Not applicableCanada
Ketoprofen-E Ect 100mgtablet (enteric-coated)100 mgoralPro Doc Limitee1996-12-312009-07-23Canada
Ketoprofen-E Ect 50mgtablet (enteric-coated)50 mgoralPro Doc Limitee1995-12-312009-07-23Canada
Ketoprofen-SR - Srt 200mgtablet (extended-release)200 mgoralPro Doc Limitee1997-09-182009-07-23Canada
Novo-keto Suppositories 100mgsuppository100 mgrectalNovopharm Limited1996-12-312005-08-10Canada
Novo-keto-EC Tab 100mgtablet (enteric-coated)100 mgoralNovopharm Limited1992-12-312005-08-10Canada
Novo-keto-EC Tab 50mgtablet (enteric-coated)50 mgoralNovopharm Limited1992-12-312005-08-10Canada
Nu-ketoprofen Cap 50mgcapsule50 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-ketoprofen-E Ect 100mgtablet (enteric-coated)100 mgoralNu Pharm Inc1994-12-312012-09-04Canada
Nu-ketoprofen-E Ect 50mgtablet (enteric-coated)50 mgoralNu Pharm Inc1994-12-312012-09-04Canada
Orafen - Sup RT 100mgsuppository100 mgrectalTechnilab Pharma Inc.1996-12-312004-08-03Canada
Orudis 100suppository100 mgrectalAventis Pharma Inc1979-12-312003-07-22Canada
Orudis 50suppository50 mgrectalAventis Pharma Inc1991-12-312003-07-22Canada
Orudis Cap 50mgcapsule50 mgoralAventis Pharma Inc1979-12-312004-07-30Canada
Orudis E-100tablet (enteric-coated)100 mgoralAventis Pharma Inc1987-12-312003-07-22Canada
Orudis E-50tablet (enteric-coated)50 mgoralAventis Pharma Inc1983-12-312004-07-30Canada
Orudis SR-200tablet (extended-release)200 mgoralAventis Pharma Inc1988-12-312005-08-01Canada
Oruvail 150capsule (sustained-release)150 mgoralAventis Pharma Inc1991-12-312003-07-22Canada
Oruvail 200capsule (sustained-release)200 mgoralAventis Pharma Inc1991-12-312003-07-22Canada
PMS-ketoprofensuppository50 mgrectalPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofensuppository100 mgrectalPharmascience Inc1993-12-31Not applicableCanada
PMS-ketoprofen Capsulescapsule50 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofen E-100 - Ecttablet (enteric-coated)100 mgoralPharmascience Inc1995-12-31Not applicableCanada
PMS-ketoprofen E-50 - Ect 50mgtablet (enteric-coated)50 mgoralPharmascience Inc1995-12-31Not applicableCanada
Rhodissuppository100 mgrectalSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhodis Cap 50mgcapsule50 mgoralRhodiapharm Inc1988-12-312005-08-01Canada
Rhodis ECtablet (enteric-coated)50 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhodis ECtablet (enteric-coated)100 mgoralSanofi Aventis Canada Inc1988-12-312007-01-11Canada
Rhodis SR 200mgtablet (extended-release)200 mgoralRhodiapharm Inc1995-12-312005-08-01Canada
Rhovail 150capsule (sustained-release)150 mgoralRhodiapharm Inc1995-12-312005-08-01Canada
Rhovail 200capsule (sustained-release)200 mgoralRhodiapharm Inc1995-12-312005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketoprofencapsule50 mg/1oralRebel Distributors Corp2010-04-20Not applicableUs
Ketoprofencapsule50 mg/1oralbryant ranch prepack2011-01-18Not applicableUs
Ketoprofencapsule50 mg/1oralTeva Pharmaceuticals USA Inc1993-01-01Not applicableUs
Ketoprofencapsule50 mg/1oralPhysicians Total Care, Inc.1997-02-14Not applicableUs
Ketoprofencapsule50 mg/1oralAv Kare, Inc.2013-07-082016-03-11Us
Ketoprofencapsule, extended release200 mg/1oralMylan Pharmaceuticals Inc.2003-09-04Not applicableUs
Ketoprofencapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-04-20Not applicableUs
Ketoprofencapsule75 mg/1oralRebel Distributors Corp2010-04-20Not applicableUs
Ketoprofentablet75 mg/1oralRed Pharm Drug Inc.2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralTeva Pharmaceuticals USA Inc1993-01-01Not applicableUs
Ketoprofencapsule75 mg/1oralPhysicians Total Care, Inc.2005-08-15Not applicableUs
Ketoprofencapsule75 mg/1oralAv Kare, Inc.2013-07-082016-03-11Us
Ketoprofencapsule50 mg/1oralSTAT Rx USA LLC2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralProficient Rx LP1993-01-01Not applicableUs
Ketoprofencapsule75 mg/1oralAidarex Pharmaceuticals LLC1993-01-01Not applicableUs
Ketoprofencapsule75 mg/1oralPreferred Pharmaceuticals, Inc.2011-01-18Not applicableUs
Ketoprofencapsule50 mg/1oralMylan Pharmaceuticals Inc.1997-01-15Not applicableUs
Ketoprofencapsule, extended release200 mg/1oralPhysicians Total Care, Inc.2009-06-23Not applicableUs
Ketoprofencapsule50 mg/1oralH.J. Harkins Company, Inc.2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralSTAT Rx USA LLC2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralbryant ranch prepack2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralRebel Distributors Corp2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralMylan Pharmaceuticals Inc.1997-01-15Not applicableUs
Ketoprofencapsule75 mg/1oralPd Rx Pharmaceuticals, Inc.2011-01-18Not applicableUs
Ketoprofencapsule75 mg/1oralA S Medication Solutions Llc1993-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vopac - Ketoprofen, Lidocaine Hydrochloride PackitSircle Laboratories, Llc2015-03-01Not applicableUs
International Brands
NameCompany
ActronNot Available
AlrheumunTeofarma
CapistenKissei
EpatecZeria Shinyaku
FastumMenarini
MenaminDaiko Seiyaku
OrudisAbbott
Orudis KTSanofi
OrugesicSanofi
OruvailWyeth
OscorelSanofi
ProfenidSanofi
ToprecSanofi
Brand mixturesNot Available
SaltsNot Available
Categories
UNII90Y4QC304K
CAS number22071-15-4
WeightAverage: 254.2806
Monoisotopic: 254.094294314
Chemical FormulaC16H14O3
InChI KeyInChIKey=DKYWVDODHFEZIM-UHFFFAOYSA-N
InChI
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
IUPAC Name
2-(3-benzoylphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • 2-phenylpropanoic-acid
  • Phenylacetate
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Ketone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
PharmacodynamicsKetoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Mechanism of actionThe anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Related Articles
AbsorptionKetoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Volume of distributionNot Available
Protein binding99% bound, primarily to albumin
Metabolism

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

SubstrateEnzymesProduct
Ketoprofen
Not Available
Ketoprofen glucuronideDetails
Route of eliminationIn a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
Half lifeConventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

Clearance
  • Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
  • Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
  • 0.08 L/kg/h
  • 0.7 L/kg/h [alcoholic cirrhosis patients]
ToxicityLD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ketoprofen Action PathwayDrug actionSMP00085
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7132
P-glycoprotein inhibitor INon-inhibitor0.9168
P-glycoprotein inhibitor IINon-inhibitor0.9589
Renal organic cation transporterNon-inhibitor0.8818
CYP450 2C9 substrateNon-substrate0.7183
CYP450 2D6 substrateNon-substrate0.9598
CYP450 3A4 substrateNon-substrate0.7685
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9604
CYP450 2C19 inhibitorNon-inhibitor0.9465
CYP450 3A4 inhibitorNon-inhibitor0.9598
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.9801
CarcinogenicityNon-carcinogens0.6299
BiodegradationReady biodegradable0.6701
Rat acute toxicity2.2378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9661
hERG inhibition (predictor II)Non-inhibitor0.9595
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Elan pharmaceutical research corp
  • Mylan pharmaceuticals inc
  • Watson laboratories inc florida
  • Wyeth pharmaceuticals inc
  • Heritage pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wyeth ayerst laboratories
  • Novartis consumer health inc
  • Bayer healthcare llc
  • L perrigo co
  • Wyeth consumer healthcare
Packagers
Dosage forms
FormRouteStrength
Capsuleoral50 mg/1
Capsuleoral50 mg
Capsuleoral75 mg/1
Capsule, extended releaseoral200 mg/1
Tabletoral75 mg/1
Tablet (extended-release)oral200 mg
Tablet (enteric-coated)oral100 mg
Tablet (enteric-coated)oral50 mg
Capsule (sustained-release)oral150 mg
Capsule (sustained-release)oral200 mg
Suppositoryrectal100 mg
Suppositoryrectal50 mg
Kit
Prices
Unit descriptionCostUnit
Ketoprofen powder43.74USD g
Ketoprofen micronized powder3.84USD g
Ketoprofen CR 200 mg 24 Hour Capsule2.8USD capsule
Orudis 75 mg capsule1.58USD capsule
Apo-Keto Sr 200 mg Sustained-Release Tablet1.46USD tablet
Ketoprofen 75 mg capsule1.12USD capsule
Pms-Ketoprofen 100 mg Suppository1.1USD suppository
Ketoprofen 50 mg capsule1.0USD capsule
Apo-Keto-E 100 mg Enteric-Coated Tablet0.71USD tablet
Apo-Keto 50 mg Capsule0.35USD capsule
Apo-Keto-E 50 mg Enteric-Coated Tablet0.35USD tablet
Orudis kt 12.5 mg tablet0.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point94 °CU.S. Patent 3,641,127.
water solubility51 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.12SANGSTER (1993)
logS-3.7ADME Research, USCD
pKa4.45SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0213 mg/mLALOGPS
logP3.29ALOGPS
logP3.61ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.52 m3·mol-1ChemAxon
Polarizability26.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Attilio Citterio, Daniele Fancelli, “Method of preparing ketoprofen.” U.S. Patent US4845281, issued December, 1982.

US4845281
General References
  1. Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [PubMed:3526298 ]
  2. Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [PubMed:16274258 ]
External Links
ATC CodesM01AE03M02AA10M01AE53
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (160 KB)
MSDSDownload (75.9 KB)
Interactions
Drug Interactions
Drug
AbciximabKetoprofen may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Ketoprofen can be decreased when combined with Abiraterone.
AcebutololKetoprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac.
AcenocoumarolKetoprofen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ketoprofen.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen.
Alendronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.
AliskirenKetoprofen may decrease the antihypertensive activities of Aliskiren.
AlprenololKetoprofen may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketoprofen.
AmikacinKetoprofen may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideKetoprofen may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ketoprofen.
AncrodKetoprofen may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.
Antithrombin III humanKetoprofen may increase the anticoagulant activities of Antithrombin III human.
ApixabanKetoprofen may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Apremilast.
AprepitantThe metabolism of Ketoprofen can be increased when combined with Aprepitant.
ArdeparinKetoprofen may increase the anticoagulant activities of Ardeparin.
ArgatrobanKetoprofen may increase the anticoagulant activities of Argatroban.
ArotinololKetoprofen may decrease the antihypertensive activities of Arotinolol.
AtenololKetoprofen may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen.
BalsalazideKetoprofen may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ketoprofen.
BecaplerminKetoprofen may increase the anticoagulant activities of Becaplermin.
BefunololKetoprofen may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketoprofen.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen.
BenoxaprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Benoxaprofen.
BetaxololKetoprofen may decrease the antihypertensive activities of Betaxolol.
BevantololKetoprofen may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen.
BisoprololKetoprofen may decrease the antihypertensive activities of Bisoprolol.
BivalirudinKetoprofen may increase the anticoagulant activities of Bivalirudin.
BopindololKetoprofen may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.
BufuralolKetoprofen may decrease the antihypertensive activities of Bufuralol.
BumetanideKetoprofen may decrease the diuretic activities of Bumetanide.
BupranololKetoprofen may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketoprofen.
CapecitabineThe metabolism of Ketoprofen can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Ketoprofen.
CarbamazepineThe metabolism of Ketoprofen can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen.
CarteololKetoprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolKetoprofen may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ketoprofen.
CeliprololKetoprofen may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Ketoprofen can be increased when it is combined with Ceritinib.
CertoparinKetoprofen may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen.
CholecalciferolThe metabolism of Ketoprofen can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen.
Citric AcidKetoprofen may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketoprofen.
ClotrimazoleThe metabolism of Ketoprofen can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineKetoprofen may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Ketoprofen can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with D-Limonene.
Dabigatran etexilateKetoprofen may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib.
DalteparinKetoprofen may increase the anticoagulant activities of Dalteparin.
DanaparoidKetoprofen may increase the anticoagulant activities of Danaparoid.
DaunorubicinKetoprofen may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.
DelavirdineThe metabolism of Ketoprofen can be decreased when combined with Delavirdine.
DesirudinKetoprofen may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketoprofen.
DextranKetoprofen may increase the anticoagulant activities of Dextran.
Dextran 40Ketoprofen may increase the anticoagulant activities of Dextran 40.
Dextran 70Ketoprofen may increase the anticoagulant activities of Dextran 70.
Dextran 75Ketoprofen may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen.
DicoumarolKetoprofen may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ketoprofen.
DihydrostreptomycinKetoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketoprofen.
DoxorubicinKetoprofen may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneKetoprofen may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam.
Edetic AcidKetoprofen may increase the anticoagulant activities of Edetic Acid.
EdoxabanKetoprofen may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Ketoprofen can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketoprofen.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketoprofen.
EnoxaparinKetoprofen may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Epirizole.
EpirubicinKetoprofen may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneKetoprofen may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.
EsmololKetoprofen may decrease the antihypertensive activities of Esmolol.
Etacrynic acidKetoprofen may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.
Ethyl biscoumacetateKetoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ketoprofen.
EtofenamateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib.
EtravirineThe metabolism of Ketoprofen can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Ketoprofen is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ketoprofen.
FloxuridineThe metabolism of Ketoprofen can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Ketoprofen can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunixin.
FluorouracilThe metabolism of Ketoprofen can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen.
FluvastatinThe metabolism of Ketoprofen can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Ketoprofen can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen.
Fondaparinux sodiumKetoprofen may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen.
FosphenytoinThe metabolism of Ketoprofen can be increased when combined with Fosphenytoin.
FramycetinKetoprofen may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideKetoprofen may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketoprofen.
GemfibrozilThe metabolism of Ketoprofen can be decreased when combined with Gemfibrozil.
GentamicinKetoprofen may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.
HeparinKetoprofen may increase the anticoagulant activities of Heparin.
HirulogKetoprofen may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Ketoprofen is combined with HMPL-004.
HydralazineKetoprofen may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen.
Hygromycin BKetoprofen may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant.
IdarubicinKetoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.
IndenololKetoprofen may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Ketoprofen can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.
IndoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketoprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Isoxicam.
KanamycinKetoprofen may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Kebuzone.
KetoconazoleThe metabolism of Ketoprofen can be decreased when combined with Ketoconazole.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen.
LabetalolKetoprofen may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Leflunomide.
LepirudinKetoprofen may increase the anticoagulant activities of Lepirudin.
LevobunololKetoprofen may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ketoprofen.
LithiumThe serum concentration of Lithium can be increased when it is combined with Ketoprofen.
LornoxicamThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Ketoprofen.
LovastatinThe metabolism of Ketoprofen can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketoprofen.
LumacaftorThe serum concentration of Ketoprofen can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.
MesalazineKetoprofen may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ketoprofen.
MetamizoleThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.
MetipranololKetoprofen may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.
MetoprololKetoprofen may decrease the antihypertensive activities of Metoprolol.
MetrizamideKetoprofen may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Ketoprofen can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ketoprofen.
NadololKetoprofen may decrease the antihypertensive activities of Nadolol.
NadroparinKetoprofen may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen.
NCX 4016The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 4016.
NeomycinKetoprofen may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nepafenac.
NetilmicinKetoprofen may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Ketoprofen can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.
OlsalazineKetoprofen may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ketoprofen.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Ketoprofen.
OmeprazoleThe metabolism of Ketoprofen can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Orgotein.
OtamixabanKetoprofen may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.
OxprenololKetoprofen may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Parecoxib.
ParomomycinKetoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololKetoprofen may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateKetoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketoprofen.
PhenindioneKetoprofen may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Ketoprofen can be increased when combined with Phenobarbital.
PhenprocoumonKetoprofen may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen.
PhenytoinThe metabolism of Ketoprofen can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.
PindololKetoprofen may decrease the antihypertensive activities of Pindolol.
PiretanideKetoprofen may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.
PlicamycinKetoprofen may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen.
PractololKetoprofen may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Ketoprofen.
PrimidoneThe metabolism of Ketoprofen can be increased when combined with Primidone.
ProbenecidThe serum concentration of Ketoprofen can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Propacetamol.
PropranololKetoprofen may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Ketoprofen.
Protein CKetoprofen may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeKetoprofen may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Ketoprofen is combined with PTC299.
PuromycinKetoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Ketoprofen can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen.
QuinineThe metabolism of Ketoprofen can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketoprofen.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.
ResveratrolThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.
ReviparinKetoprofen may increase the anticoagulant activities of Reviparin.
RibostamycinKetoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Ketoprofen can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ketoprofen can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.
RivaroxabanKetoprofen may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ketoprofen.
SalicylamideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen.
SalsalateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ketoprofen.
SecobarbitalThe metabolism of Ketoprofen can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Seratrodast.
SildenafilThe metabolism of Ketoprofen can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Ketoprofen can be decreased when combined with Sorafenib.
SotalolKetoprofen may decrease the antihypertensive activities of Sotalol.
SpectinomycinKetoprofen may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketoprofen.
SpironolactoneKetoprofen may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Ketoprofen is combined with SRT501.
StreptomycinKetoprofen may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinKetoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Ketoprofen can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole.
SulfasalazineKetoprofen may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen.
SulfisoxazoleThe metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen.
SulodexideKetoprofen may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.
TacrolimusKetoprofen may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Ketoprofen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketoprofen.
TenofovirThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen.
TepoxalinThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Ketoprofen can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Ketoprofen can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronate.
TimololKetoprofen may decrease the antihypertensive activities of Timolol.
TobramycinKetoprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Ketoprofen can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.
TorasemideKetoprofen may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ketoprofen.
TranilastThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.
TriamtereneKetoprofen may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.
TrimethoprimThe metabolism of Ketoprofen can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ketoprofen.
Valproic AcidThe metabolism of Ketoprofen can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketoprofen.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Ketoprofen.
VoriconazoleThe metabolism of Ketoprofen can be decreased when combined with Voriconazole.
WarfarinKetoprofen may increase the anticoagulant activities of Warfarin.
XimelagatranKetoprofen may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Ketoprofen can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ketoprofen.
Zoledronic acidThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected.
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B: Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000 Aug;12(8):766-73. [PubMed:10929089 ]
  2. Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354 ]
  3. Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718 ]
  4. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823 ]
  5. Levoin N, Blondeau C, Guillaume C, Grandcolas L, Chretien F, Jouzeau JY, Benoit E, Chapleur Y, Netter P, Lapicque F: Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen. Biochem Pharmacol. 2004 Nov 15;68(10):1957-69. [PubMed:15476667 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904 ]
  2. Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9. [PubMed:11729362 ]
  3. Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7. [PubMed:11814865 ]
  4. Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718 ]
  5. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Interleukin-8 receptor activity
Specific Function:
Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity.
Gene Name:
CXCR1
Uniprot ID:
P25024
Molecular Weight:
39790.735 Da
References
  1. Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F: 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. [PubMed:15974585 ]
  2. Bizzarri C, Pagliei S, Brandolini L, Mascagni P, Caselli G, Transidico P, Sozzani S, Bertini R: Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem Pharmacol. 2001 Jun 1;61(11):1429-37. [PubMed:11331079 ]
  3. Wang LM, Toyoshima A, Mineshita S, Wang XX, Yamamoto T, Nomura Y, Yang L, Koikei Y, Shiba K, Honda Y: The anti-inflammatory effects of ketoprofen in animal experiments. Drugs Exp Clin Res. 1997;23(1):1-6. [PubMed:9093816 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C: Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. Chirality. 2001 Jul;13(7):372-8. [PubMed:11400191 ]
  2. Lagrange F, Penhourcq F, Matoga M, Bannwarth B: Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal. 2000 Oct;23(5):793-802. [PubMed:11022905 ]
  3. Li F, Zhou D, Guo X: Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis. J Chromatogr Sci. 2003 Mar;41(3):137-41. [PubMed:12725696 ]
  4. Zhou D, Li F: [Study of protein binding in ketoprofen using liquid chromatography frontal analysis in comparison with capillary electrophoresis frontal analysis]. Se Pu. 2004 Nov;22(6):601-4. [PubMed:15807110 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807 ]
  2. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697 ]
  5. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  2. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. [PubMed:12358729 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
  2. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818 ]
  3. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23